Literature DB >> 19018671

Immunological recovery and metabolic disorders in severe immunodeficiency HIV type 1-infected children on highly active antiretroviral therapy.

Salvador Resino1, Dariela Micheloud, Beatriz Larrú, Jose M Bellón, Juan Antonio Léon, Rosa Resino, M Isabel De José, M Dolores Gurbindo Gutiérrez, M José Mellado, Sara Guillen, José Tomas Ramos, M Angeles Muñoz-Fernández.   

Abstract

Little is known about immunologic reconstitution in children on highly active antiretroviral treatment (HAART) during very long-term periods. A retrospective study was carried out to assess the effectiveness and development of metabolic disorders after very long-term periods on HAART in HIV-infected children with severe immunodeficiency. We included 55 children who were stratified into three groups according to %CD4(+) pre-HAART and rate of immunologic recovery: (1) S1-Rec: CD4(+) < or =5% at baseline and slow immunologic recovery; (2) S2-Rec: CD4(+) 5-15% at baseline and slow immunologic recovery; (3) R-Rec: CD4(+) < or =15% at baseline and rapid immunologic recovery (reference group). An adequate immune recovery after 8 years on HAART was achieved by only 25% of children. S1-Rec never achieved a mean of CD4(+) > or =25% after 8 years on HAART. All children had a significant increase in plasma cholesterol levels during the first 2 years. Afterward, cholesterol levels reached a plateau and remained stable until year 8 of follow-up. Higher rates of lipodystrophy were found in the R-Rec group [14 (100%)] than in the S1-Rec group [9/19 (47.4%)] or the S2-Rec group [13/20 (65%)] at the end of the study (p = 0.006). Overall, having a low nadir of CD4(+) hindered immune reconstitution; however, children with rapid immunologic recovery showed a higher prevalence of the lipodystrophy syndrome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19018671     DOI: 10.1089/aid.2008.0037

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  5 in total

1.  Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation.

Authors:  Dwight E Yin; Meredith G Warshaw; William C Miller; Hannah Castro; Susan A Fiscus; Lynda M Harper; Linda J Harrison; Nigel J Klein; Joanna Lewis; Ann J Melvin; Gareth Tudor-Williams; Ross E McKinney
Journal:  Pediatrics       Date:  2014-10       Impact factor: 7.124

2.  Preservation of lymphocyte functional fitness in perinatally-infected and treated HIV+ pediatric patients displaying sub-optimal viral control.

Authors:  Aaruni Khanolkar; William J Muller; Bridget M Simpson; Jillian Cerullo; Ruth Williams; Sun Bae Sowers; Kiana Matthews; Sara Mercader; Carole J Hickman; Richard T D'Aquila; Guorong Liu
Journal:  Commun Med (Lond)       Date:  2022-03-04

3.  Recovery of effective HIV-specific CD4+ T-cell activity following antiretroviral therapy in paediatric infection requires sustained suppression of viraemia.

Authors:  Emily Adland; Luisa Mori; Leana Laker; Anna Csala; Maximilian Muenchhoff; Alice Swordy; Masa Mori; Philippa Matthews; Gareth Tudor-Williams; Pieter Jooste; Philip Goulder
Journal:  AIDS       Date:  2018-07-17       Impact factor: 4.177

4.  Hypercholesterolemia is associated with the apolipoprotein C-III (APOC3) genotype in children receiving HAART: an eight-year retrospective study.

Authors:  Carlos A Rocco; Debora Mecikovsky; Paula Aulicino; Rosa Bologna; Luisa Sen; Andrea Mangano
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

Review 5.  Metabolic complications and treatment of perinatally HIV-infected children and adolescents.

Authors:  Linda Barlow-Mosha; Allison Ross Eckard; Grace A McComsey; Philippa M Musoke
Journal:  J Int AIDS Soc       Date:  2013-06-18       Impact factor: 5.396

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.